NO2014005I1 - olodaterol, syreaddisjonssalter og farmakologisk akseptable syrer derav - Google Patents

olodaterol, syreaddisjonssalter og farmakologisk akseptable syrer derav

Info

Publication number
NO2014005I1
NO2014005I1 NO2014005C NO2014005C NO2014005I1 NO 2014005 I1 NO2014005 I1 NO 2014005I1 NO 2014005 C NO2014005 C NO 2014005C NO 2014005 C NO2014005 C NO 2014005C NO 2014005 I1 NO2014005 I1 NO 2014005I1
Authority
NO
Norway
Prior art keywords
olodaterol
acid addition
addition salts
pharmacologically acceptable
acceptable acids
Prior art date
Application number
NO2014005C
Other languages
English (en)
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32185709&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2014005(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of NO2014005I1 publication Critical patent/NO2014005I1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO2014005C 2002-11-15 2014-03-10 olodaterol, syreaddisjonssalter og farmakologisk akseptable syrer derav NO2014005I1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10253282A DE10253282A1 (de) 2002-11-15 2002-11-15 Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung
PCT/EP2003/012565 WO2004045618A2 (de) 2002-11-15 2003-11-11 Neue arzneimittel zur behandlung von chronisch obstruktiver lungenerkrankung

Publications (1)

Publication Number Publication Date
NO2014005I1 true NO2014005I1 (no) 2014-03-10

Family

ID=32185709

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20052883A NO334314B1 (no) 2002-11-15 2005-06-14 Forbindelser, farmasøytiske formuleringer inneholdende slike samt anvendelse av disse for fremstilling av medikamenter for behandling av kronisk obstruktiv lungesykdom
NO2014005C NO2014005I1 (no) 2002-11-15 2014-03-10 olodaterol, syreaddisjonssalter og farmakologisk akseptable syrer derav

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20052883A NO334314B1 (no) 2002-11-15 2005-06-14 Forbindelser, farmasøytiske formuleringer inneholdende slike samt anvendelse av disse for fremstilling av medikamenter for behandling av kronisk obstruktiv lungesykdom

Country Status (38)

Country Link
EP (2) EP2025338A1 (no)
JP (1) JP4317138B2 (no)
KR (1) KR101092247B1 (no)
CN (3) CN101817800A (no)
AR (2) AR041969A1 (no)
AT (1) ATE430569T1 (no)
AU (1) AU2003285326B2 (no)
BE (1) BE2014C016I2 (no)
BR (1) BRPI0316264B8 (no)
CA (1) CA2506082C (no)
CO (1) CO5570670A2 (no)
CY (2) CY1110500T1 (no)
DE (2) DE10253282A1 (no)
DK (1) DK1562603T3 (no)
EA (1) EA008665B1 (no)
EC (1) ECSP055774A (no)
ES (1) ES2326878T7 (no)
FR (1) FR14C0049I2 (no)
HR (1) HRP20050432B1 (no)
HU (1) HUS1400011I1 (no)
IL (1) IL167900A (no)
LT (1) LTC1562603I2 (no)
LU (1) LU92433I2 (no)
ME (1) ME00354B (no)
MX (1) MXPA05005081A (no)
MY (1) MY136034A (no)
NL (1) NL300650I2 (no)
NO (2) NO334314B1 (no)
NZ (1) NZ540661A (no)
PE (1) PE20040694A1 (no)
PL (1) PL212238B1 (no)
PT (1) PT1562603E (no)
RS (1) RS51607B (no)
SI (1) SI1562603T1 (no)
TW (1) TWI343812B (no)
UA (1) UA81276C2 (no)
WO (1) WO2004045618A2 (no)
ZA (1) ZA200502246B (no)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
DE102004019539A1 (de) * 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von Atemwegserkrankungen
PT2422786E (pt) * 2004-04-22 2014-11-12 Boehringer Ingelheim Int Novas combinações farmacêuticas para o tratamento de doenças respiratórias
EP1789394A1 (de) * 2004-05-13 2007-05-30 Boehringer Ingelheim International Gmbh Hydroxy-substituierte benzkondensierte heterozyklen als betaagonisten zur behandlung von atemwegserkrankungen
DE102004024452A1 (de) * 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolformulierung für die Inhalation von Betaagonisten
DE102004024453A1 (de) * 2004-05-14 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Bronchodilatoren zur Behandlung von Atemwegserkrankungen
US7745621B2 (en) 2004-05-14 2010-06-29 Boehringer Ingelheim International Gmbh Long acting bronchodilators for the treatment of respiratory diseases
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
US20050256115A1 (en) * 2004-05-14 2005-11-17 Boehringer Ingelheim International Gmbh Aerosol formulation for the inhalation of beta-agonists
DE102004024451A1 (de) * 2004-05-14 2005-12-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierungen für die Inhalation, die Enantiomerenreine Betaagonisten enthalten
DE102004024454A1 (de) * 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Enantiomerenreine Betaagonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
DE102004045648A1 (de) * 2004-09-21 2006-03-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Betamimetika zur Behandlung von Atemwegserkrankungen
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
DE102005007654A1 (de) 2005-02-19 2006-08-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
DE102005030733A1 (de) * 2005-07-01 2007-01-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen enthaltend langwirksame Beta-2-Agonisten und wenigstens einen weiteren Wirkstoff
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
BRPI0614290A2 (pt) 2005-08-08 2011-03-22 Argenta Discovery Ltd derivados de biciclo [ 2.2.1 ] hept-7-ilamina e seus usos
AU2006281449B2 (en) * 2005-08-15 2013-01-31 Boehringer Ingelheim International Gmbh Method for producing betamimetics
US20070088030A1 (en) 2005-10-10 2007-04-19 Barbara Niklaus-Humke Aerosol formulations for the inhalation of beta-agonists
US20070086957A1 (en) 2005-10-10 2007-04-19 Thierry Bouyssou Combination of medicaments for the treatment of respiratory diseases
CA2625664C (en) 2005-10-21 2016-01-05 Novartis Ag Human antibodies against il13 and therapeutic uses
EA200801139A1 (ru) * 2005-11-09 2008-10-30 Бёрингер Ингельхайм Интернациональ Гмбх Композиция для аэрозольной ингаляции
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
JP2009526817A (ja) * 2006-02-16 2009-07-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器疾患の治療用医薬組成物
PE20080142A1 (es) 2006-03-15 2008-04-14 Boehringer Ingelheim Int Beta-agonistas enantiomericamente puros y sus procedimientos de preparacion
ATE549337T1 (de) 2006-04-21 2012-03-15 Novartis Ag Purinderivate zur verwendung als adenosin-a2a- rezeptoragonisten
US20100222336A1 (en) * 2006-08-07 2010-09-02 Boehringer Ingelheim International Gmbh Single enantiomer beta-agonists, methods for the production thereof and the use thereof as medication
UY30542A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de agonistas beta
UY30543A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de beta- agonistas
WO2008037477A1 (en) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines as p13k lipid kinase inhibitors
AU2007315234A1 (en) 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
PL2104535T3 (pl) 2007-01-10 2011-05-31 Irm Llc Związki i kompozycje jako inhibitory proteazy aktywujące kanały
KR101456872B1 (ko) * 2007-01-25 2014-10-31 베링거 인겔하임 인터내셔날 게엠베하 베타미메틱의 제조방법
ES2361595T3 (es) 2007-05-07 2011-06-20 Novartis Ag Compuestos orgánicos.
MX2010006421A (es) 2007-12-10 2010-06-25 Novartis Ag Compuestos organicos.
MX2010007604A (es) 2008-01-11 2010-08-02 Novartis Ag Pirimidinas como inhibidores de cinasa.
BRPI0915018A2 (pt) 2008-06-10 2015-10-27 Novartis Ag compostos orgânicos
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
SG172444A1 (en) 2008-12-30 2011-07-28 Pulmagen Therapeutics Inflammation Ltd Sulfonamide compounds for the treatment of respiratory disorders
WO2010088335A1 (en) 2009-01-29 2010-08-05 Novartis Ag Substituted benzimidazoles for the treatment of astrocytomas
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
BR112012003262A8 (pt) 2009-08-12 2016-05-17 Novartis Ag compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação
IN2012DN01961A (no) 2009-08-17 2015-08-21 Intellikine Llc
EP2490687A1 (en) 2009-10-22 2012-08-29 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
EP2618827B1 (en) * 2010-09-21 2021-06-02 Intekrin Therapeutics, Inc. Antidiabetic solid pharmaceutical compositions
WO2012107500A1 (en) 2011-02-10 2012-08-16 Novartis Ag [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
EP2678016B1 (en) 2011-02-23 2016-08-10 Intellikine, LLC Heterocyclic compounds and uses thereof
BR112013021638A2 (pt) 2011-02-25 2016-08-02 Irm Llc "compostos inibidores de trk, seu uso e composições que os compreendem"
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
MX339302B (es) 2011-09-15 2016-05-19 Novartis Ag 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como cinasas de tirosina.
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
JP6165733B2 (ja) 2011-09-16 2017-07-19 ノバルティス アーゲー Ｎ−置換ヘテロシクリルカルボキサミド類
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038386A1 (en) 2011-09-16 2013-03-21 Novartis Ag Heterocyclic compounds for the treatment of cystic fibrosis
WO2013078440A2 (en) 2011-11-23 2013-05-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
ES2894830T3 (es) 2012-04-03 2022-02-16 Novartis Ag Productos combinados con inhibidores de tirosina·cinasa y su uso
JP2015533131A (ja) * 2012-10-09 2015-11-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 咳を治療するためのベータ２−アドレナリン受容体作動薬
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
WO2014151147A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
JP6404944B2 (ja) 2014-04-24 2018-10-17 ノバルティス アーゲー ホスファチジルイノシトール３−キナーゼ阻害薬としてのピラジン誘導体
MX2016013981A (es) 2014-04-24 2016-11-15 Novartis Ag Derivados de amino-piridina como inhibidores de fosfatidil-inositol-3-cinasa.
CA2945212A1 (en) 2014-04-24 2015-10-29 Novartis Ag Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
US10195208B2 (en) 2014-07-31 2019-02-05 Novartis Ag Combination therapy
WO2018108669A1 (en) 2016-12-12 2018-06-21 Boehringer Ingelheim International Gmbh Nintedanib for use in methods for the treatment of interstitial lung diseases by coadministration with olodaterol
WO2018114887A1 (en) 2016-12-20 2018-06-28 Laboratorios Lesvi, S.L. Improved process for the manufacture of r-6-hydroxy-8-[1-hydroxy-2-[2-(4-methoxyphenyl)-1,1-dimethylethylaminoethyl]-2h-1,4-benzoxazin-3(4h)-one hydrochloride
CN108997248B (zh) * 2018-08-06 2023-08-01 上海方予健康医药科技有限公司 盐酸奥达特罗晶型b及其制备方法
CN109096218B (zh) * 2018-08-06 2020-10-27 上海方予健康医药科技有限公司 盐酸奥达特罗晶型a及其制备方法
KR20220019015A (ko) 2019-06-10 2022-02-15 노파르티스 아게 Cf, copd, 및 기관지확장증 치료를 위한 피리딘 및 피라진 유도체
WO2021038426A1 (en) 2019-08-28 2021-03-04 Novartis Ag Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease
CN115768404A (zh) * 2020-06-09 2023-03-07 广州谷森制药有限公司 含乌美溴铵和三苯乙酸维兰特罗的药物制剂
US11331322B1 (en) 2021-09-15 2022-05-17 Santen Pharmaceutical Co., Ltd. Medicament for preventing and/or treating dry eye

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3134590A1 (de) * 1981-09-01 1983-03-10 Boehringer Ingelheim KG, 6507 Ingelheim Neue benzo-heterocyclen
US4460581A (en) 1982-10-12 1984-07-17 Boehringer Ingelheim Kg (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones
DE3743265A1 (de) * 1987-12-19 1989-06-29 Boehringer Ingelheim Kg Neue ammoniumverbindungen, ihre herstellung und verwendung
HUP0300832A2 (hu) * 2000-04-27 2003-08-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Új, lassú hatású bétamimetikumok, eljárás előállításukra és alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények

Also Published As

Publication number Publication date
CY2014032I2 (el) 2015-12-09
MXPA05005081A (es) 2005-07-01
EP1562603B3 (de) 2014-01-08
PE20040694A1 (es) 2004-11-23
ECSP055774A (es) 2005-11-22
JP4317138B2 (ja) 2009-08-19
CY2014032I1 (el) 2015-12-09
TWI343812B (en) 2011-06-21
DE10253282A1 (de) 2004-05-27
ES2326878T3 (es) 2009-10-21
LU92433I2 (fr) 2014-06-24
UA81276C2 (en) 2007-12-25
PL375270A1 (en) 2005-11-28
MEP53608A (en) 2011-05-10
BR0316264A (pt) 2005-10-11
CA2506082C (en) 2011-06-21
AU2003285326B2 (en) 2009-06-04
AR041969A1 (es) 2005-06-01
TW200423943A (en) 2004-11-16
EP1562603A2 (de) 2005-08-17
KR101092247B1 (ko) 2011-12-12
CN101735166A (zh) 2010-06-16
AU2003285326A1 (en) 2004-06-15
HRP20050432B1 (en) 2012-01-31
PL212238B1 (pl) 2012-08-31
JP2006508140A (ja) 2006-03-09
KR20050075013A (ko) 2005-07-19
IL167900A (en) 2013-06-27
NO20052883L (no) 2005-06-14
RS20050361A (en) 2007-04-10
DE50311502D1 (de) 2009-06-18
HRP20050432A2 (en) 2006-06-30
BRPI0316264B8 (pt) 2021-05-25
BE2014C016I2 (no) 2023-03-07
PT1562603E (pt) 2009-06-18
FR14C0049I2 (fr) 2015-07-24
CY1110500T1 (el) 2015-04-29
EP1562603B1 (de) 2009-05-06
ES2326878T7 (es) 2014-03-11
ME00354B (me) 2011-10-10
EP2025338A1 (de) 2009-02-18
HUS1400011I1 (hu) 2022-02-28
EA008665B1 (ru) 2007-06-29
DK1562603T3 (da) 2009-09-07
FR14C0049I1 (no) 2014-08-08
CN1713914A (zh) 2005-12-28
WO2004045618A3 (de) 2004-09-30
RS51607B (sr) 2011-08-31
MY136034A (en) 2008-07-31
NZ540661A (en) 2007-12-21
CO5570670A2 (es) 2005-10-31
ZA200502246B (en) 2006-01-25
NO334314B1 (no) 2014-02-03
WO2004045618A2 (de) 2004-06-03
ATE430569T1 (de) 2009-05-15
SI1562603T1 (sl) 2009-10-31
NL300650I2 (nl) 2017-11-02
EA200500715A1 (ru) 2005-12-29
LTC1562603I2 (lt) 2016-12-12
BRPI0316264B1 (pt) 2019-04-09
CA2506082A1 (en) 2004-06-03
AR087241A2 (es) 2014-03-12
CN101817800A (zh) 2010-09-01

Similar Documents

Publication Publication Date Title
NO2014005I1 (no) olodaterol, syreaddisjonssalter og farmakologisk akseptable syrer derav
NO2014021I1 (no) Bedaquiline eller et farmasøytisk akseptabelt syre- eller baseaddisjonssalt derav
NO2023030I1 (no) Apixaban and pharmaceutical acceptable salts thereof
NO2009013I1 (no) laropiprant eller et farmasoytisk akseptabelt saltderav, og eventuelt nikotinsyre
NO20034669D0 (no) Karboksylsyrederivat og salt derav
NO2015016I1 (no) Vorapaxar, eller et farmasøytisk akseptabelt salt eller solvat derav
NO2013007I1 (no) Dapagliflozin og farmasøytisk akseptable salter derav
NO2014011I2 (no) Vortioksetin eller et farmasøytisk akseptabelt syreaddisjonssalt dera
DK1207868T3 (da) Farmaceutiske tramadolsalte
DK1660431T3 (da) Phenoxyeddikesyrederivater
NO20033815L (no) Farmasöytiske salter
NO20053143D0 (no) Farmasoytiske sammensetninger omfattende en basisk, henholdsvis sur legemiddelforbindelse, en sufaktant og en fysiologisk akseptabel vannloselig syre henholdsvis base.
NO20052855D0 (no) Fosfonoksykinazolinderivater og farmasoytisk anvendelse derav.
ATE384696T1 (de) Mandelsäure derivate
NO20054969D0 (no) 2-cyanopropansyreamid- og esterderivater og deres anvendelse
IS8231A (is) Lyfjafræðilega gagnleg sölt karboxýlsýruafleiða
DE50212761D1 (de) Neuartige aminodicarbonsäurederivate
IS7575A (is) Própíónsýruafleiður og notkun þeirra sem HPPAR virkjar
ATE410407T1 (de) Zimtsäureamidderivate
NO20040389L (no) Nye vinylkarboksylsyrederivater og deres anvendelse som antidiabetika
IS8232A (is) Lyfjafræðilega gagnleg sölt karboxýlsýruafleiða
NO20043349L (no) Kumarinderivater, fremgangsmate for deres framstilling og anvendelse derav
NO20052975D0 (no) Nye 2',5'-oligoadenylsyreanaloger.
DK1556382T3 (da) 3-Phenylpyridoindolderivater, fremstilling og terapeutisk anvendelse deraf
DK1551814T3 (da) Chirale oxazol-arylpropionsyrederivater og anvendelse deraf som ppar-agnister